Literature DB >> 25941343

Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia.

Marlies Penning1, Jamie S Chua2, Cees van Kooten1, Malu Zandbergen1, Aletta Buurma1, Joke Schutte1, Jan Anthonie Bruijn1, Eliyahu V Khankin1, Kitty Bloemenkamp1, S Ananth Karumanchi1, Hans Baelde1.   

Abstract

A growing body of evidence suggests that complement dysregulation plays a role in the pathogenesis of preeclampsia. The kidney is one of the major organs affected in preeclampsia. Because the kidney is highly susceptible to complement activation, we hypothesized that preeclampsia is associated with renal complement activation. We performed a nationwide search for renal autopsy material in the Netherlands using a computerized database (PALGA). Renal tissue was obtained from 11 women with preeclampsia, 25 pregnant controls, and 14 nonpregnant controls with hypertension. The samples were immunostained for C4d, C1q, mannose-binding lectin, properdin, C3d, C5b-9, IgA, IgG, and IgM. Preeclampsia was significantly associated with renal C4d-a stable marker of complement activation-and the classical pathway marker C1q. In addition, the prevalence of IgM was significantly higher in the kidneys of the preeclamptic women. No other complement markers studied differed between the groups. Our findings in human samples were validated using a soluble fms-like tyrosine kinase 1 mouse model of preeclampsia. The kidneys in the soluble fms-like tyrosine kinase 1-injected mice had significantly more C4 deposits than the control mice. The association between preeclampsia and renal C4d, C1q, and IgM levels suggests that the classical complement pathway is involved in the renal injury in preeclampsia. Moreover, our finding that soluble fms-like tyrosine kinase 1-injected mice develop excess C4 deposits indicates that angiogenic dysregulation may play a role in complement activation within the kidney. We suggest that inhibiting complement activation may be beneficial for preventing the renal manifestations of preeclampsia.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  C4d; complement; hypertension kidney; preeclampsia; proteinuria; sFlt-1

Mesh:

Substances:

Year:  2015        PMID: 25941343      PMCID: PMC4465860          DOI: 10.1161/HYPERTENSIONAHA.115.05484

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  50 in total

1.  eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype.

Authors:  Feng Li; John R Hagaman; Hyung-Suk Kim; Nobuyo Maeda; J Charles Jennette; James E Faber; S Ananth Karumanchi; Oliver Smithies; Nobuyuki Takahashi
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

2.  Natural IgM antibodies are involved in the activation of complement by hypoxic human tubular cells.

Authors:  Pieter van der Pol; Anja Roos; Stefan P Berger; Mohamed R Daha; Cees van Kooten
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-02

3.  Factor H as a regulator of the classical pathway activation.

Authors:  Uday Kishore; Robert B Sim
Journal:  Immunobiology       Date:  2011-07-23       Impact factor: 3.144

4.  A renal biopsy study in toxaemia of pregnancy.

Authors:  C R Tribe; G E Smart; D R Davies; J C Mackenzie
Journal:  J Clin Pathol       Date:  1979-07       Impact factor: 3.411

5.  Renal morphology in preeclampsia.

Authors:  H L Sheehan
Journal:  Kidney Int       Date:  1980-08       Impact factor: 10.612

Review 6.  Pros and cons for C4d as a biomarker.

Authors:  Danielle Cohen; Robert B Colvin; Mohamed R Daha; Cinthia B Drachenberg; Mark Haas; Volker Nickeleit; Jane E Salmon; Banu Sis; Ming-Hui Zhao; Jan A Bruijn; Ingeborg M Bajema
Journal:  Kidney Int       Date:  2012-02-01       Impact factor: 10.612

7.  Targeted inhibition of complement activation prevents features of preeclampsia in mice.

Authors:  Xiaoping Qing; Patricia B Redecha; Melissa A Burmeister; Stephen Tomlinson; Vivette D D'Agati; Robin L Davisson; Jane E Salmon
Journal:  Kidney Int       Date:  2010-10-13       Impact factor: 10.612

8.  Endothelial growth factor therapy improves preeclampsia-like manifestations in a murine model induced by overexpression of sVEGFR-1.

Authors:  Julio Mateus; Egle Bytautiene; Fangxian Lu; Esther H Tamayo; Ancizar Betancourt; Gary D V Hankins; Monica Longo; George R Saade
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-02       Impact factor: 4.733

9.  Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia.

Authors:  Wei Wang; Roxanna A Irani; Yujin Zhang; Susan M Ramin; Sean C Blackwell; Lijian Tao; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2012-08-06       Impact factor: 10.190

10.  Immunofluorescent studies in renal biopsies in pre-eclampsia.

Authors:  O M Petrucco; N M Thomson; J R Lawrence; M W Weldon
Journal:  Br Med J       Date:  1974-03-16
View more
  21 in total

Review 1.  From Glomerular Endothelium to Podocyte Pathobiology in Preeclampsia: a Paradigm Shift.

Authors:  Rosanne J Turner; Kitty W M Bloemenkamp; Marlies E Penning; Jan Anthonie Bruijn; Hans J Baelde
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

2.  Role of IgM and angiotensin II Type I receptor autoantibodies in local complement activation in placental ischemia-induced hypertension in the rat.

Authors:  Jean F Regal; Megan E Strehlke; Jenna M Peterson; Cameron R Wing; Jordan E Parker; Noel Fernando Nieto; Lynne T Bemis; Jeffrey S Gilbert; Sherry D Fleming
Journal:  Mol Immunol       Date:  2016-08-30       Impact factor: 4.407

Review 3.  Preeclampsia and Pregnancy-Related Hypertensive Disorders.

Authors:  S Ananth Karumanchi; Joey P Granger
Journal:  Hypertension       Date:  2015-12-22       Impact factor: 10.190

4.  Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction.

Authors:  Bhavisha A Bakrania; Frank T Spradley; Heather A Drummond; Babbette LaMarca; Michael J Ryan; Joey P Granger
Journal:  Compr Physiol       Date:  2020-12-09       Impact factor: 9.090

5.  Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice.

Authors:  Nicola Garrett; Joaquim Pombo; Michelle Umpierrez; James E Clark; Mark Simmons; Guillermina Girardi
Journal:  JCI Insight       Date:  2018-04-19

Review 6.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

Review 7.  Antibodies against Angiotensin II Type 1 and Endothelin A Receptors: Relevance and pathogenicity.

Authors:  Mary Carmelle Philogene; Tory Johnson; Arthur Jason Vaught; Sammy Zakaria; Neal Fedarko
Journal:  Hum Immunol       Date:  2019-04-19       Impact factor: 2.850

8.  Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.

Authors:  Mimi Y Kim; Marta M Guerra; Elianna Kaplowitz; Carl A Laskin; Michelle Petri; D Ware Branch; Michael D Lockshin; Lisa R Sammaritano; Joan T Merrill; T Flint Porter; Allen Sawitzke; Anne M Lynch; Jill P Buyon; Jane E Salmon
Journal:  Ann Rheum Dis       Date:  2018-01-25       Impact factor: 19.103

9.  Complement 7 Is Up-Regulated in Human Early Diabetic Kidney Disease.

Authors:  Monica Sircar; Ivy A Rosales; Martin K Selig; Dihua Xu; Zsuzsanna K Zsengeller; Isaac E Stillman; Towia A Libermann; S Ananth Karumanchi; Ravi I Thadhani
Journal:  Am J Pathol       Date:  2018-10       Impact factor: 4.307

10.  VEGF regulates local inhibitory complement proteins in the eye and kidney.

Authors:  Lindsay S Keir; Rachel Firth; Lyndsey Aponik; Daniel Feitelberg; Susumu Sakimoto; Edith Aguilar; Gavin I Welsh; Anna Richards; Yoshihiko Usui; Simon C Satchell; Valeryia Kuzmuk; Richard J Coward; Jonathan Goult; Katherine R Bull; Ruchi Sharma; Kapil Bharti; Peter D Westenskow; Iacovos P Michael; Moin A Saleem; Martin Friedlander
Journal:  J Clin Invest       Date:  2016-12-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.